Document K6NGJE83KYyJeOeDnZe3g10po

Relevant studies include mammals that have undergone non-acute exposure to Cape Fear PFCs and biomonitoring of workers who and their children. PFOA and PFOS are excluded from this list. Please note there are duplicate reports for certain PFCs. GenX Salt - CAS 62037-80-3 February 8, 2008 "Company Sanitized" Mice, male - repeat dose, 7 day - oral gavage Two-fold elevations in all liver weight parameters Changes in liver for mice given 30kg/mg: minimal single cell necrosis of hepatocytes, moderate hepatocellular hypertrophy, moderate increases in mitotic figures May 23, 2008 "Company Sanitized" Mice and Rats, male & female - repeat dose, 28 day - oral gavage, 28 day recovery Doses were 0, 0.3, 3, 30 mg/kg for males and 0, 3, 30, 300 mg/kg for females Statistically significant increases in kidney and liver weights for male rats in 3 and 30 mg/kg/d groups. All organ weight changes were reversible (in recovery period) Statistically significant increases in kidney and liver weights for male & female mice in 3 and 30 mg/kg/d groups. All organ weight changes were not completely reversible (in recovery period) September 16, 2009 (DuPont) Rats, male & female - 90 day oral toxicity - 30d recovery period Male doses: 0.1, 10, 100 mg/kg/day; Female doses: 10, 100, 1000 mg/kg/day Most of the 1000 mg/kg/day females exhibited intermittent wet clear material around the mouth at the time of dosing and approximately 1-2 hours post-dosing. Two 100 mg/ks/day males exhibited wet clear material around the mouth on 2 days at the time of dosing. One 100 mg/kg/day male vocalized during handling on one occasion Kidney and liver weights increased for high done male/females Microscopic findings in two of the 1000 mg/kg/day females that died (nos. 73 15 and 73 18) were similar, suggesting that these deaths were test substance related. Female no. 7315 (found dead on study day 21) had microscopic lesions of renal tubular necrosis, renal papillary necrosis, hepatocellular hypertrophy, and lymphoid depletion in multiple tissues. Female no. 73 18 (found dead on study day 37) had microscopic lesions of renal papillary necrosis, hyperplasia of the transitional epithelium of the urinary bladder, coagulation necrosis of portions of an adrenal gland, hepatocellular hypertrophy, and lymphoid depletion in multiple tissues PMN: P-08-0508 (for CAS 13252-13-6) December 29, 2009 (DuPont) Mice, young male & female - 90 day oral toxicity Dose: 0, 0.1, 0.5, or 5 mg/kg/day Increased liver weight, reduced cholesterol in males. No substance-related deaths, neurobehavioral, clinical or ophthalmological observations PMN: P-08-0509 (for CAS 62037-80-3) February 5, 2010 (DuPont) Rats - Developmental toxicity - Dosing from gestation day 6 to 20 Dose: 0, 10, 100, or 1000 mg/kg/day Dose related increase to the number of dams found with early deliveries on gestation day 21 There were 0, 0, 4, and 9 dams found delivered at 0, 10, 100, and 1000 mg/kg/day, respectively. In addition, mean fetal weight was 8 and 28% lower than controls at 100 and 1000 mg/kg/day, respectively; these reductions were statistically significant. Slight reductions in maternal body weight and food consumption occurred at 1000 mg/kg/day. Maternal kidney weights were significantly higher at 1000 mg/kg/day and maternal liver weights were significantly higher at 100 and 1000 mg/kg/day PMN: P-08-0509 (for CAS 62037-80-3) July 15, 2010 (DuPont) Mice, male & female - Reproductive and developmental toxicity - preliminary (See next) At 5 mg/kg/day, a statistically significant increase in body weights/gains, food consumption, liver weights (42% in males and 102% in females) and kidney weights (8% in males, which is not statistically significant and 21% in females) compared to controls Lower body weights of offspring PMN: P-08-0509 (for CAS 62037-80-3) July 20, 2010 (DuPont) Final results for previous study (July 15, 2010) January 8, 2013 (DuPont) Rats, male & female - 2 year oral toxicity study Lengthy list of significant changes are in the document PFBA - CAS 375-22-4 August 26, 2005 (3M) Initial Quantitative Screening of Human Serum (obtained in 2004) for Endogenous Fluorochemicals December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals December 2008 (3M) Analysis of the Homologous Series of Perfluorocarboxylates - Perfluorobutanoate (C4) through Perfluorododecanoate (C12) from American Red Cross Adult Blood Donors, 2006 600 plasma samples collected May/June 2006 PFPeA - CAS 2706-90-3 August 26, 2005 (3M) Initial Quantitative Screening of Human Serum (obtained in 2004) for Endogenous Fluorochemicals Follow-up study is next December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals PFPeA was a fluorochemicals that was screened January 9, 2013 (Taft) Submitted the following paper relating human health effects to PFOA and PFCs: o Javins, B., et aL', "Circulating Maternal Pertluoroalkyl Substances during Pregnancy in the C8 Health Study," Environ. Sci. & Tech. (dol:- 10.1021/es3028082) (on-line Jan. 7, 2013); o Dong, G-H., et al, "Serum Polyfluoroalkyl Concentrations, Asthma Outcomes, and Immunological Markers in a Case-Control Study of Taiwanese Children," Environ. Health Perspec. (dx.doi.org/10.1289/ehp.1205351) (on-line Jan. 8, 2013); o 3. Vieira, V.M., et al., "Perfluorooctanoic Acid Exposure and Cancer Outcomes in a Contaminated Community: A Geographic Analysis," Environ. Health Perspec. (dx.doi.org/1 0. 1 289/ehp. 1205829) (on-line Jan. 8, 2013). PFHxA - CAS 307-24-4 September 2003 (3M) Provides a master index of studies submitted under TSCA 8(e) by 3M. CBI is redacted so it is borderline useless August 26, 2005 (3M) Initial Quantitative Screening of Human Serum (obtained in 2004) for Endogenous Fluorochemicals Follow-up study is next December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals PFPeA was a fluorochemicals that was screened May 27, 2009 (DuPont) Occupational serum results for PFHxA at the West VA facility June 25, 2009 (DuPont) Occupational Serum Sample Results for PFHxA January 9, 2013 (Taft) Submitted the following paper relating human health effects to PFOA and PFCs: o Javins, B., et aL', "Circulating Maternal Pertluoroalkyl Substances during Pregnancy in the C8 Health Study," Environ. Sci. & Tech. (dol:- 10.1021/es3028082) (on-line Jan. 7, 2013); o Dong, G-H., et al, "Serum Polyfluoroalkyl Concentrations, Asthma Outcomes, and Immunological Markers in a Case-Control Study of Taiwanese Children," Environ. Health Perspec. (dx.doi.org/10.1289/ehp.1205351) (on-line Jan. 8, 2013); o 3. Vieira, V.M., et al., "Perfluorooctanoic Acid Exposure and Cancer Outcomes in a Contaminated Community: A Geographic Analysis," Environ. Health Perspec. (dx.doi.org/1 0. 1 289/ehp. 1205829) (on-line Jan. 8, 2013). PFHpA - CAS 375-85-9 August 26, 2005 (3M) Initial Quantitative Screening of Human Serum (obtained in 2004) for Endogenous Fluorochemicals Follow-up study is next December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals PFPeA was a fluorochemicals that was screened January 9, 2013 (Taft) Submitted the following paper relating human health effects to PFOA and PFCs: o Javins, B., et aL', "Circulating Maternal Pertluoroalkyl Substances during Pregnancy in the C8 Health Study," Environ. Sci. & Tech. (dol:- 10.1021/es3028082) (on-line Jan. 7, 2013); o Dong, G-H., et al, "Serum Polyfluoroalkyl Concentrations, Asthma Outcomes, and Immunological Markers in a Case-Control Study of Taiwanese Children," Environ. Health Perspec. (dx.doi.org/10.1289/ehp.1205351) (on-line Jan. 8, 2013); o 3. Vieira, V.M., et al., "Perfluorooctanoic Acid Exposure and Cancer Outcomes in a Contaminated Community: A Geographic Analysis," Environ. Health Perspec. (dx.doi.org/1 0. 1 289/ehp. 1205829) (on-line Jan. 8, 2013). PFNA - CAS 375-95-1 September 17, 2004 (Company Sanitized) Worker monitoring data from blood levels of 281 people at 3 different production lines. August 26, 2005 (3M) Initial Quantitative Screening of Human Serum (obtained in 2004) for Endogenous Fluorochemicals Follow-up study is next December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals PFPeA was a fluorochemicals that was screened November 12, 2012 (3M) PFCs in the Tennessee River Results of Potential PFC Sources PFDA - CAS 335-76-2 September 17, 2004 (Company Sanitized) Worker monitoring data from blood levels of 281 people at 3 different production lines. August 26, 2005 (3M) Initial Quantitative Screening of Human Serum (obtained in 2004) for Endogenous Fluorochemicals Follow-up study is next December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals PFPeA was a fluorochemicals that was screened PFBS - CAS 375-73-5 August 26, 2005 (3M) Initial Quantitative Screening of Human Serum (obtained in 2004) for Endogenous Fluorochemicals Follow-up study is December 2005 November 25, 2005 (3M) Analysis of PFBS, PFHS, PFOS, and PFOA in Water Samples Collected at 3M Guin December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals PFPeA was a fluorochemicals that was screened April 12, 2006 (3M) May 30, 2006 (3M) November 15, 2006 (3M) February 26, 2007 (3M) March 13, 2008 (3M) May 28, 2008 (3M) February 24, 2011 (3M) October 27, 2011 (3M) July 5, 2012 (3M) November 19, 2012 (3M)  Site related monitoring of groundwater, surface water, wells, soils, fish, etc February 16, 2010 (3M) Submitted paper: Princen and Pieterman. 2009. Mechanism of the effect of different PFAS's (PFBS vs PFHS vs PFOS) on lipid and lipoprotein metabolism in APOE*3-Leiden/huCETP transgenic mice. PFHxS 355-46-4 May 15, 2001 & June 7 2001 (3M) Reported results of PFCs measured in stored human serum September 5, 2001 (3M) Giesy and Kannan. 2002. Accumulation of PFOS and related PFCs in marine mammals. September 24, 2003 (3M) Master list of submitted TSCA documents (much is redacted) from 3M August 26, 2005 (3M) Initial Quantitative Screening of Human Serum (obtained in 2004) for Endogenous Fluorochemicals December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals November 16, 2005 (3M) Serum samples of children of two female fluorochemical plant workers November 25, 2005 (3M) Analysis of PFBS, PFHS, PFOS, and PFOA in Water Samples Collected at 3M Guin December 19, 2005 (3M) Definitive Study: Quantitative Screening of Human Serum for Endogenous Fluorochemicals PFPeA was a fluorochemicals that was screened February 16, 2010 (3M) Effect of PFOS and PFHS on body weight, food consumption, and serum cholesterol in mice January 9, 2013 (Taft) Submitted the following paper relating human health effects to PFOA and PFCs: o Javins, B., et aL', "Circulating Maternal Pertluoroalkyl Substances during Pregnancy in the C8 Health Study," Environ. Sci. & Tech. (dol:- 10.1021/es3028082) (on-line Jan. 7, 2013); o Dong, G-H., et al, "Serum Polyfluoroalkyl Concentrations, Asthma Outcomes, and Immunological Markers in a Case-Control Study of Taiwanese Children," Environ. Health Perspec. (dx.doi.org/10.1289/ehp.1205351) (on-line Jan. 8, 2013); o 3. Vieira, V.M., et al., "Perfluorooctanoic Acid Exposure and Cancer Outcomes in a Contaminated Community: A Geographic Analysis," Environ. Health Perspec. (dx.doi.org/1 0. 1 289/ehp. 1205829) (on-line Jan. 8, 2013). April 14, 2006 (3M) May 30, 2006 (3M) November 15, 2006 (3M) February 26, 2007 (3M) November 28, 2007 (3M) March 13, 2008 (3M) May 28, 2008 (3M) August 6, 2008 (3M) Site related monitoring of groundwater, surface water, wells, soils, fish, etc PFMOAA 674-13-5 No Files PFMOPrA 377-73-1 No Files PFMOBA 863090-89-5 No Files PFPrOPrA - GenX* 13252-13-6 Consent Order Available, No Section 8(e) Filings available PFO2HxA 39492-88-1 No Files PFO3OA 39492-89-2 No Files PFO4DA 39492-90-5 No Files